Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Depot Buprenorphine (RBP-6000) with Different Polymer Molecular Weights in OUD
NCT02559973Phase 1Completed
- Sponsor
- Indivior
- Start
- Sep 2015
- Primary completion
- Feb 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) (3 arms), sponsored by Indivior. Primary endpoints: Area Under the Concentration-Time Curve from Study Day 1 to Day 29 of Buprenorphine and Maximum Observed Plasma Concentration of Buprenorphine. Started Sep 2015; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02559973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559973.